CSL is a global biotechnology company headquartered in Melbourne, Australia, and one of the world's largest producers of plasma-derived and recombinant therapies. Founded in 1916 as the Commonwealth Serum Laboratories, CSL has grown into a USD 13 billion revenue company with operations in more than 35 countries and manufacturing facilities across Australia, the US, Europe and Asia.
The company's CSL Behring division is a world leader in plasma therapies for immunology, haematology, critical care and infectious disease, while CSL Seqirus is a top global influenza vaccine manufacturer, and CSL Vifor focuses on iron deficiency and nephrology. CSL operates one of the world's largest plasma collection networks, with over 300 collection centres.
For B2B buyers, CSL supplies plasma-derived therapies, vaccines and specialty pharmaceuticals to hospitals, distributors and government health programs worldwide. Its manufacturing excellence, regulatory track record and R&D pipeline make it a critical partner in the global biopharmaceutical supply chain.
